AI Detects Heart Failure in 5 Seconds 💓

🔬 The Big Story

FDA fast‑tracks a voice‑based AI that can detect worsening heart failure

Noah Labs just secured FDA breakthrough device designation for Noah Labs Vox, a five‑second voice‑analysis tool trained on more than 3 million audio samples. The system monitors subtle vocal biomarkers linked to fluid buildup and cardiac stress — giving clinicians a way to spot deterioration weeks before hospitalization.

The algorithm has already been validated with Mayo Clinic, UCSF, Charité Berlin, and global partners, and a new clinical trial is now underway. As CEO Oliver Piepenstock puts it, “voice is a powerful predictor for worsening heart failure,” and early detection could fundamentally shift how clinicians intervene and prevent adverse outcomes.

👉 Source → Noah Labs - A breakthrough for heart failure.

⚡ Quick Hits

🔸Stroke may “rejuvenate” the healthy side of the brain, AI study finds

USC’s Stevens INI and the ENIGMA Stroke Recovery group studied MRI scans from over 500 stroke survivors, discovering that the damaged hemisphere shows accelerated aging, while the opposite side appears structurally younger. This effect is most pronounced in the contralesional frontoparietal network, linked to planning, attention, and coordination.

👉 Source → Associations between contralesional neuroplasticity and motor impairment through deep learning-derived MRI regional brain age in chronic stroke (ENIGMA): a multicohort, retrospective, observational study - The Lancet Digital Health

🔸Your clinic can now have a real conversational front desk

This voice agent, using gpt-realtime-1.5, manages patient interactions from start to finish. It naturally converses, collects clinical and scheduling details, and books appointments instantly, creating a seamless, automated experience that integrates with a clinic's existing systems without extra operational burden.

👉 Source → OpenAI Developers on X

🔸Lilly just locked in a $2.75B AI drug pipeline — without buying the company

Eli Lilly signed a sweeping licensing deal with Insilico that gives it exclusive rights to a portfolio of oral small‑molecule drugs — all designed by Insilico’s Pharma.AI platform since the two began collaborating in 2023.

👉 Source → Eli Lilly reaches deal to bring AI-developed drugs to global market

🌍 Beyond AI

A pill that cuts LDL by 60%. No injections. No barriers. Real cardiovascular impact.

This one isn’t about AI. But it’s too important to ignore.

A new phase‑three trial in The New England Journal of Medicine found that enlicitide — an oral PCSK9 inhibitor — lowered LDL cholesterol by about 60%, matching the power of injectable therapies. Most participants were already on statins and still far above target levels, underscoring how many patients never reach safe LDL ranges.

The process is well-known: enlicitide stops PCSK9, allowing the liver to remove LDL more effectively. The key change is how it's given — as a daily pill instead of an injection. The study involved 2,909 adults with artery disease or high risk; enlicitide also lowered non-HDL cholesterol, ApoB, and lipoprotein(a), with benefits lasting for a year.

It’s one of the clearest demonstrations yet that a simple oral therapy could finally close the gap between what’s possible in cardiology and what patients actually receive.

👉 Source → A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide | New England Journal of Medicine